PsiOxus-Therapeutics News-Web-12_edited.jpg

News Archives

November 15, 2018

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy

December 12, 2017

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

August 16, 2017

PsiOxus Therapeutics Announce Two New Board Appointments: Strengthens US Presence

June 13, 2017

PsiOxus Therapeutics Expands operations in both Oxford, UK and Philadelphia, USA

December 20, 2016

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors

November 15, 2016

PsiOxus Therapeutics Licenses Immunotherapeutic Delivery Technology ‘Polymap

September 16, 2016

PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US

June 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

March 10, 2016

PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study

January 7, 2016

PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board